| Proposed Ticker: NORI | 10260 Bubb Road | |
| Exchange: NASDAQ-National Market | Cupertino, California 95014 | |
| Industry: Manufacturing | (408) 252-6800 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 5/9/96 | |
| U.S. Shares Filed: | 3,000,000 | Filing Range: | $12.00 - $14.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $39,000,000 | |
| Primary Shares: | 3,000,000 | Expenses: | $900,000 | |
| Secondary Shares: | 0 | Shs Out After: | 12,368,641 | |
| Manager | Tier | Phone |
| Alex. Brown & Sons Incorporated | Lead Manager | (410) 727-1700 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/96 | 3/31/96 | ||
| Revenue: | $0.15 | $0.04 | $0.04 | Assets: | $18.15 |
| Net Income: | -$5.86 | -$2.28 | -$1.47 | Liabilities: | $1.48 |
| EPS: | -$0.71 | -$0.26 | Equity: | $16.67 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Norian develops, manufactures and markets Norian Skeletal Repair System a proprietary bone fixation and replacement material designed for use in regions of structurally compromised cancellous bone such as the wrist, hip, knee and spine. Norian SRS is inserted into bone defects as a paste, either through minimally invasive injection or in an open surgical procedure. The material sets within 10 minutes of application and continues to cure over 12 hours to achieve its ultimate strength. The Company believes that Norian SRS provides direct structural support to compromised cancellous bone and can withstand compressive mechanical force soon after a procedure and over time. Additionally, Norian SRS may reduce the need for orthopaedic hardware in weakened cancellous bone. Norian SRS cures into a crystalline structure similar to the mineral phase of natural bone and appears to be replaced by natural bone over time. The Company intends to seek regulatory approval of Norian SRS as a cancellous bone cement. Under an Investigational Device Exemption ("IDE") approved by the United States Food and Drug Administration ("FDA"), the Company is conducting a randomized, multi-center clinical trial of the use of Norian SRS in the treatment of wrist fractures in up to 324 patients. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund expansion of manufacturing, marketing and sales activities, clinical trials of Norian SRS, research and development activities and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.